Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study

Sirivichayakul, Chukiat; Barranco-Santana, Elizabeth A; Esquilin-Rivera, Inés; Oh, H. M. L.; Raanan, Marsha G.; Sariol, Carlos A.; Shek, Lynette Pei‐Chi; Simasathien, Sriluck; Smith, Mia J.; Vélez, Iván Darío; Wallace, Derek; Gordon, Gary G.; Stinchcomb, Dan T.

doi:10.1093/infdis/jiv762

Cited by 74 publications

(58 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because of the unusual capacity of ZIKV to be transmitted sexually and to cross the placenta, LAVs for ZIKV will be most effective as a childhood vaccine delivered prior to sexual maturity. While the safety profile of many chimeric flaviviruses has been excellent (Kirkpatrick et al, 2016; Sirivichayakul et al, 2016), use of the currently available DENV LAV is limited to those greater than nine years of age (Guy and Jackson, 2016; Hadinegoro et al, 2015). Clinical studies to establish the safety of ZIKV LAVs in an adolescent population will be required.…”

Section: Zikv Vaccine Developmentmentioning

confidence: 99%

Zika Virus: Immunity and Vaccine Development

Pierson

Graham

2016

Cell

115

View full text Add to dashboard Cite

show abstract

Section: Zikv Vaccine Developmentmentioning

confidence: 99%

Zika Virus: Immunity and Vaccine Development

Pierson

Graham

2016

Cell

115

View full text Add to dashboard Cite

show abstract

“…The reactogenicity did not increase with successive vaccination and was not higher in children than in adults and adolescents. Others have also reported of the efficacy of TDV in clinical studies [32][33][34][35][36]. The safety profiles of this vaccine have been evaluated.…”

Section: Methods Of Data Collectionmentioning

confidence: 99%

“…Although TDV is safe, a number of adverse events have been reported. Sirivichayakal et al [34] reported of the following solicited adverse events (AEs): injection site pain, itching and erythema which was mostly mild while Rupp et al reported of the following unsolicited AEs: headache, fatigue, myalgia and injection site pain [38].…”

Section: Methods Of Data Collectionmentioning

confidence: 99%

Advances in Dengue Vaccine: A Review Study

Yaro¹

2016

JHVRV

View full text Add to dashboard Cite

Dengue is now a global burden with about 3.97 billion people living in 128 countries at risk and 400 million infections occurring every year. Four closely related serotypes have been implicated in the global burden: DENV 1-4. It has been reported that there are serotype specific differences in clinical manifestations. This systematic review is based on PRISMA guidelines. It discusses two types of DENV vaccine based on inclusion criteria: Tetravalent dengue vaccine (TDV) and dengue DNA vaccine that are in clinical studies. A number of studies evaluated the safety, reactogenicity, and immunogenicity of TDV especially Sanofi Pasteur's CYD-TDV. Most of the studies reported that the vaccine candidate is safe and elicit efficient neutralizing antibody. As part of the global effort to develop DENV vaccine, the US National Institute of Health also initiated a program which culminated in the development of a monovalent dengue vaccine candidate called rDEN4∆30. Five different formulation were evaluated in clinical studies. Only a paper described a randomized controlled study of DENV DNA vaccine. It reported that the vaccine candidate is safe at the given dose. Studies are needed to evaluate the immunological profile of dengue vaccine in children and those in endemic areas. The future of DENV vaccine effort looks bright and it is hoped that soon an efficient DENV vaccine will be available for human use.

show abstract

“…Pathogens are also eliminated through herbal agents as well as anti-viral amalgamations are in use against dengue virus. New modified anti-viral agents (against all four serotypes) that are safe, inexpensive but effective at the same time are, however, a growing need [9,37,38].…”

Section: Control and Vaccinationmentioning

confidence: 99%